Filing Details
- Accession Number:
- 0001209191-20-010560
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-19 16:39:59
- Reporting Period:
- 2020-02-17
- Accepted Time:
- 2020-02-19 16:39:59
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1789815 | Ourania Tatsis | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Svp, Cro | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2020-02-17 | 597 | $241.50 | 16,349 | No | 4 | F | Direct | |
Common Stock | Disposition | 2020-02-18 | 160 | $241.82 | 16,189 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-18 | 528 | $242.78 | 15,661 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-18 | 160 | $243.78 | 15,501 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-18 | 286 | $244.99 | 15,215 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-18 | 145 | $245.75 | 15,070 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | F | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $241.82 (range $241.33 to $242.18).
- Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $242.78 (range $242.38 to $243.31).
- Open market sales reported on this line occurred at a weighted average price of $243.78 (range $243.42 to $244.23).
- Open market sales reported on this line occurred at a weighted average price of $244.99 (range $244.52 to $245.30).
- Open market sales reported on this line occurred at a weighted average price of $245.75 (range $245.54 to $245.85).